1,863 Shares in Edwards Lifesciences Corporation (EW) Acquired by Checchi Capital Advisers LLC

Checchi Capital Advisers LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, Holdings Channel reports. The firm bought 1,863 shares of the medical research company’s stock, valued at approximately $220,000.

Several other large investors have also added to or reduced their stakes in EW. YorkBridge Wealth Partners LLC acquired a new stake in Edwards Lifesciences Corporation during the first quarter worth about $110,000. NEXT Financial Group Inc raised its stake in Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after buying an additional 500 shares during the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Edwards Lifesciences Corporation during the second quarter worth about $126,000. Cornerstone Advisors Inc. raised its stake in Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares during the last quarter. Finally, Alexandria Capital LLC raised its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares during the last quarter. 84.67% of the stock is owned by institutional investors and hedge funds.

Shares of Edwards Lifesciences Corporation (NYSE EW) opened at 113.57 on Friday. The stock’s 50 day moving average is $116.54 and its 200 day moving average is $105.90. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.75. The firm has a market cap of $23.98 billion, a PE ratio of 34.45 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.88 by $0.20. The firm had revenue of $842 million for the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.76 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “1,863 Shares in Edwards Lifesciences Corporation (EW) Acquired by Checchi Capital Advisers LLC” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/08/18/1863-shares-in-edwards-lifesciences-corporation-ew-acquired-by-checchi-capital-advisers-llc.html.

A number of equities research analysts have recently issued reports on the stock. BidaskClub lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Canaccord Genuity reaffirmed a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research report on Thursday, June 1st. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Edwards Lifesciences Corporation in a research report on Tuesday, May 16th. They set a “conviction-buy” rating and a $138.00 price target on the stock. Finally, Cowen and Company reissued an “outperform” rating and set a $135.00 price target (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $121.13.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $115.99, for a total transaction of $3,816,071.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $114.68, for a total value of $607,804.00. The disclosure for this sale can be found here. Insiders have sold a total of 149,281 shares of company stock worth $17,331,446 over the last three months. 2.13% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit